In vitiligo, the return of pigment and the end of the disease are two different things. A patient can repigment well and still develop new patches later, and that possibility shapes nearly every treatment conversation that follows. In this episode of The Spot Check, Jamie Restivo, PA-C, talks with Nada M. Elbuluk, MD, about managing a chronic autoimmune disease whose most visible improvements arrive slowly.

Much of that work begins at the first visit. Dr Elbuluk describes how she frames the diagnosis for patients, taking care to remove any sense that they caused it, and how she distinguishes segmental from nonsegmental disease. She also discusses the clinical signs that suggest vitiligo is actively progressing, among them confetti depigmentation and Koebnerization, and what positive thyroid antibodies can signal even when thyroid function is normal.

Topical therapies can quiet the immune attack, but they do not always get melanocytes working again. This is where narrowband UVB earns its place, and Dr Elbuluk explains how she combines the two and how the distribution of disease decides between a full-body booth and targeted light. Anatomy matters as well; the face tends to respond, while the fingers, toes, and other sites with few melanocytes to draw on are another matter.

Phototherapy two to three times a week asks a great deal of patients, and the trips to the office can become an obstacle of their own. Restivo and Dr Elbuluk discuss where home units fit, including why she sometimes starts patients in the office before they invest in a device, and how she thinks about tapering once pigment has returned or response has plateaued. Toward the end of the episode, she highlights a reality often obscured by the "cosmetic" label: vitiligo dictates daily life, quietly deciding what patients wear, where they go, and which moments they skip altogether.